These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 3257159)

  • 1. Combined effects of chemotherapy and interleukin 2 in the therapy of mice with advanced pulmonary tumors.
    Papa MZ; Yang JC; Vetto JT; Shiloni E; Eisenthal A; Rosenberg SA
    Cancer Res; 1988 Jan; 48(1):122-9. PubMed ID: 3257159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ; Mulé JJ; Rosenberg SA
    Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy of advanced solid tumors in mice using chemotherapy in combination with interleukin-2 with and without lymphokine-activated killer cells.
    Kedar E; Ben-Aziz R; Shiloni E
    Isr J Med Sci; 1988; 24(9-10):494-504. PubMed ID: 3264551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
    Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
    J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
    Lafreniere R; Rosenberg SA
    J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cure of B16F10 melanoma lung metastasis in mice by chronic indomethacin therapy combined with repeated rounds of interleukin 2: characteristics of killer cells generated in situ.
    Lala PK; Parhar RS
    Cancer Res; 1988 Mar; 48(5):1072-9. PubMed ID: 3124954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of the tumor determines the outcome of immunotherapy with interleukin-2, ABPP, and cyclophosphamide of micro- and macrometastatic intraperitoneal tumor.
    Eggermont AM; Sugarbaker PH
    Cancer Detect Prev; 1990; 14(4):483-90. PubMed ID: 2224911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide.
    Naito K; Pellis NR; Kahan BD
    Cancer Res; 1988 Jan; 48(1):101-8. PubMed ID: 3257158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced antitumor immune responses of IL-2 gene-modified tumor vaccine by combination with IL-1 and low dose cyclophosphamide.
    Cao X; Zhang W; Wan T; Yu Y; Tao Q; Wang J
    J Exp Clin Cancer Res; 1999 Jun; 18(2):173-9. PubMed ID: 10464704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
    Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
    Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo.
    Krosnick JA; Mulé JJ; McIntosh JK; Rosenberg SA
    Cancer Res; 1989 Jul; 49(14):3729-33. PubMed ID: 2736513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
    Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
    Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.
    Ettinghausen SE; Rosenberg SA
    Cancer Res; 1986 Jun; 46(6):2784-92. PubMed ID: 3486038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of interleukin 12 to low dose interleukin 2 treatment improves antitumor efficacy in vivo.
    Leder GH; Oppenheim M; Rosenstein M; Lotze MT; Beger HG
    Z Gastroenterol; 1995 Sep; 33(9):499-502. PubMed ID: 8525651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemoprotective effects of recombinant human IL-1 alpha in cyclophosphamide-treated normal and tumor-bearing mice. Protection from acute toxicity, hematologic effects, development of late mortality, and enhanced therapeutic efficacy.
    Futami H; Jansen R; MacPhee MJ; Keller J; McCormick K; Longo DL; Oppenheim JJ; Ruscetti FW; Wiltrout RH
    J Immunol; 1990 Dec; 145(12):4121-30. PubMed ID: 2258610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2.
    Mulé JJ; Yang JC; Afreniere RL; Shu SY; Rosenberg SA
    J Immunol; 1987 Jul; 139(1):285-94. PubMed ID: 3108401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tamoxifen potentiates in vivo antitumor activity of interleukin-2.
    Kim B; Warnaka P; Konrad C
    Surgery; 1990 Aug; 108(2):139-44; discussion 144-5. PubMed ID: 2382215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy of disseminated NK-resistant tumor by the synergistic effects of recombinant interleukin-2 and tumor necrosis factor.
    Agah R; Malloy B; Sherrod A; Bean P; Girgis E; Mazumder A
    J Biol Response Mod; 1988 Apr; 7(2):140-51. PubMed ID: 3258905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eradication of disseminated murine leukemia by treatment with high-dose interleukin 2.
    Thompson JA; Peace DJ; Klarnet JP; Kern DE; Greenberg PD; Cheever MA
    J Immunol; 1986 Dec; 137(11):3675-80. PubMed ID: 3491145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-15 mediates anti-tumor effects after cyclophosphamide injection of tumor-bearing mice and enhances adoptive immunotherapy: the potential role of NK cell subpopulations.
    Evans R; Fuller JA; Christianson G; Krupke DM; Troutt AB
    Cell Immunol; 1997 Jul; 179(1):66-73. PubMed ID: 9259773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.